Logos Global Management LP Reports 3.2% Stake in Avalo Therapeutics, Inc. (AVTX)

On May 15, 2026, Logos Global Management LP and its affiliates filed a Schedule 13G/A for Avalo Therapeutics, Inc. (AVTX), reporting an ownership stake of 1,675,000 shares, representing 3.2% of the company. This filing marks an increase from a previously reported 0.0% position. The reported holdings consist of 675,000 shares of common stock and options to acquire an additional 1,000,000 shares. The reporting group includes Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Dr. William Arsani, who serves as a control person for these entities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The percentage calculation is based on 52,565,517 shares of common stock outstanding as of May 8, 2026. All reporting persons share voting and dispositive power over the disclosed shares.